Grifols SA

Grifols S.A. regains investor focus amid short‑seller allegations and stock volatility—learn how recent scrutiny could shape future earnings and share value.

Grifols SA stock shows modest 3‑year gains as plasma‑derived markets grow; €10.15 share price, €6.65 bn cap, and a 10.3 % CAGR for plasma fractionation highlight future upside.